Edwards Lifesciences (NYSE:EW) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of Edwards Lifesciences (NYSE:EW) from a hold rating to a buy rating in a report issued on Saturday morning,Wall Street Zen reports.

Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. UBS Group initiated coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price target on the stock. Evercore reiterated an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a report on Monday, July 6th. Finally, Mizuho boosted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Stock Down 2.6%

Shares of NYSE:EW opened at $84.54 on Friday. Edwards Lifesciences has a 52-week low of $72.30 and a 52-week high of $96.29. The stock has a market cap of $48.68 billion, a P/E ratio of 48.59, a PEG ratio of 2.21 and a beta of 0.85. The business has a fifty day moving average of $89.16 and a two-hundred day moving average of $85.79. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter in the previous year, the company posted $0.67 EPS. The company’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts expect that Edwards Lifesciences will post 3 earnings per share for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel Lippis sold 619 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $87.51, for a total transaction of $54,168.69. Following the sale, the vice president directly owned 40,034 shares in the company, valued at $3,503,375.34. This represents a 1.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares of the company’s stock, valued at $1,618,200.32. This represents a 12.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 5,664 shares of company stock valued at $511,918 in the last ninety days. Company insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $266,000. NewEdge Advisors LLC increased its position in shares of Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after purchasing an additional 2,665 shares during the last quarter. Sei Investments Co. increased its position in shares of Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC raised its holdings in shares of Edwards Lifesciences by 277.7% in the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after purchasing an additional 50,924 shares in the last quarter. Finally, Treasurer of the State of North Carolina lifted its position in shares of Edwards Lifesciences by 0.4% during the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after purchasing an additional 1,065 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences News Summary

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
• Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
• Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
• Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.